Synaffix: Enables ADCs for oncology that are both safer and more effective as well as easier to manufacture




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Synaffix: Enables ADCs for oncology that are both safer and more effective as well as easier to manufacture
Released on: December 19, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform.
  • Summary
  • Participants
  • Company
Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition
Prior to joining Synaffix in 2011, Peter held various executive positions at CPS Color (now Chromaflo/Corob), including Managing Director Australia, Director Marketing & Sales APAC, Global Product Manager and Technical & Business Development Director. He received his MSc degree in Chemical Engineering from Eindhoven University of Technology (the Netherlands), an Executive MBA degree from Kellogg School of Management and a Master of Business Law (MBL) degree from Sydney University (Australia).
We are critically focused on enabling our partners with the most advanced suite of tools available for the design and development of ADCs that can be targeted against a wide variety of cancer types and can generate proof-of-concept ADCs in just a matter of weeks. Key features of Synaffix ADC technology: • No need for mAb or cell line engineering • Homogenous and stable ADC products • Compatible with any IgG isotype and all key payload classes • Efficient conjugation of highly hydrophobic payloads • Low propensity to aggregate • Site-Specific • DAR2, DAR4 and Dual-Warhead (DAR2+2) ADC formats • Rapid and predictable scalability to multi-gram scale • COGs comparable to ThioMAB ADCs